Filters








75 Hits in 2.0 sec

Social Cohesion in Autonomous Driving [article]

Nicholas C. Landolfi, Anca D. Dragan
2018 arXiv   pre-print
II-B with the new reward R c . E.  ...  C. Feature Map & Reward Parameters Prior work [2] inspires our features. We visualize examples of these in Fig. 2 .  ... 
arXiv:1808.03845v2 fatcat:civ5r7jiyfaijnarhb724dzkcm

Asking Easy Questions: A User-Friendly Approach to Active Reward Learning [article]

Erdem Bıyık, Malayandi Palan, Nicholas C. Landolfi, Dylan P. Losey, Dorsa Sadigh
2019 arXiv   pre-print
2 = 7, c 3 = 3  ...  ., Q n+k )− k i=0 c(Q n+i ) ≤ I(q n ; ω | Q n )+. . .  ... 
arXiv:1910.04365v1 fatcat:53wiv6e5rjd2lpb2gqwk6alomi

Amphiregulin and Epidermal Hyperplasia

Narasimharao Bhagavathula, Kamalakar C. Nerusu, Gary J. Fisher, Gao Liu, Archana B. Thakur, Lorraine Gemmell, Shankar Kumar, Zenghai H. Xu, Paul Hinton, Naoya Tsurushita, Nicholas F. Landolfi, John J. Voorhees (+1 others)
2005 American Journal of Pathology  
BALB/c mice were immunized and boosted twice with the recombinant protein.  ...  Cells were grown at 37°C in an atmosphere of 5% CO 2 and 95% air, and used at passages 3 to 4.  ... 
doi:10.1016/s0002-9440(10)62322-x pmid:15793282 pmcid:PMC1780140 fatcat:eargf7ldrzcvzmqcfsvveuzcqm

Learning Reward Functions from Diverse Sources of Human Feedback: Optimally Integrating Demonstrations and Preferences [article]

Erdem Bıyık, Dylan P. Losey, Malayandi Palan, Nicholas C. Landolfi, Gleb Shevchuk, Dorsa Sadigh
2021 arXiv   pre-print
Let each query Q have an associated cost c(Q) ∈ R + .  ...  For any k ≥ 0, I(q i , . . . , q i+k ; ω | Q i , . . . , Q i+k ) − k j=0 c(Q i+j ) = I(q i ; ω | Q i ) + · · · + I(q i+k ; ω | q i , . . ., q n+k−1 , Q i , . . ., Q i+k )− k j=0 c(Q i+j ) ≤ I(q i ; ω |  ... 
arXiv:2006.14091v2 fatcat:5bvuyqpte5hifaluozij2jnmla

A Model-based Approach for Sample-efficient Multi-task Reinforcement Learning [article]

Nicholas C. Landolfi and Garrett Thomas and Tengyu Ma
2019 arXiv   pre-print
When underlying dynamical model changes, we (naturally) require some samples to adapt (c) and (d). See Section 5.3 for details.  ...  Numerical experiments suggesting our algorithm can handle (a) out-of-distribution tasks, (b) a shift in dynamical model (both Figure 2) and (c) active task selection ( Figure 3 ).  ... 
arXiv:1907.04964v3 fatcat:gxhzuh5oozdldfrumarjmzcgf4

Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study [article]

Andrew Ip, Donald A Berry, Eric Hansen, Andre H Goy, Andrew L Pecora, Brittany A Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M Berry, Nicholas S Berry, Shivam Mathura, Ihor S Sawczuk (+20 others)
2020 medRxiv   pre-print
Hydroxychloroquine has been touted as a COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has been proposed as a treatment of critically ill patients. Objective: To describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Design: Retrospective observational cohort study of electronic health records Setting: 13-hospital network spanning the state of New Jersey. Participants: Patients hospitalized between March 1, 2020 and
more » ... April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Main Outcomes: The primary outcome was death. Results: Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]). The 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively. Among 547 evaluable ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival association with tocilizumab treatment (adjusted HR, 0.76 [95% CI, 0.57-1.00]), with 30 day unadjusted mortality with and without tocilizumab of 46% versus 56%. Conclusions: This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients. Tocilizumab demonstrated a trend association towards reduced mortality among ICU patients. Our findings are limited to hospitalized patients and must be interpreted with caution while awaiting results of randomized trials.
doi:10.1101/2020.05.21.20109207 fatcat:oczuswweufhgneozelrsltkp6u

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study

Andrew Ip, Donald A. Berry, Eric Hansen, Andre H. Goy, Andrew L. Pecora, Brittany A. Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M. Berry, Nicholas S. Berry, Shivam Mathura, Ihor S. Sawczuk (+21 others)
2020 PLoS ONE  
Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients. In this retrospective observational cohort study drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Patients were hospitalized at a 13-hospital network spanning New Jersey USA between March 1, 2020 and
more » ... pril 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]). The 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively. Among 547 evaluable ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival association with tocilizumab treatment (adjusted HR, 0.76 [95% CI, 0.57-1.00]), with 30 day unadjusted mortality with and without tocilizumab of 46% versus 56%. This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients. Tocilizumab demonstrated a trend association towards reduced mortality among ICU patients. Our findings are limited to hospitalized patients and must be interpreted with caution while awaiting results of randomized trials. Trial Registration: Clinicaltrials.gov Identifier: NCT04347993.
doi:10.1371/journal.pone.0237693 pmid:32790733 pmcid:PMC7425928 fatcat:3x2ufwk445h3jjml4aj36ew5nm

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial

Timothy F Cloughesy, Kevin Petrecca, Tobias Walbert, Nicholas Butowski, Michael Salacz, James Perry, Denise Damek, Daniela Bota, Chetan Bettegowda, Jay-Jiguang Zhu, Fabio Iwamoto, Dimitris Placantonakis (+18 others)
2020 JAMA Oncology  
Concept and design: Cloughesy, Butowski, Landolfi, Chen, Gruber, Ostertag, Kheoh, Kabbinavar. Acquisition, analysis, or interpretation of data: All authors.  ...  York, New York), Karen Fink (Baylor University Medical Center, Dallas, Texas), Deborah Olin Heros (University of Miami, Miami, Florida), Gelareh Zadeh (Toronto Western Hospital, Toronto, Canada), Garth Nicholas  ... 
doi:10.1001/jamaoncol.2020.3161 pmid:33119048 pmcid:PMC7596685 fatcat:4vo27ijy6vd4bolvrjllgktgxa

Page 398 of Maryland Historian Vol. 24, Issue 4 [page]

1929 Maryland Historian  
Lambson, Nicholas, 132. Lanahan, Mrs. William Wallace, elected, 383. “The Landing,” 145. “Landing Place,” 141. Landolfi, Fred, 210, Lantz, Emily Emerson, 56. Lanvale Cotton Factory, 245.  ...  C. F., elected, 385. Lemmon, Dr. Robert, 10. Lemon, John, 189, 248. “Lemons Range,” 191. “Leonards Choice,” 367. LetTer TO EILEEN. Francis Sims McGrath, 291.  ... 

Page 359 of PMLA. Publications of the Modern Language Association of America Vol. 73, Issue 2 [page]

1957 PMLA. Publications of the Modern Language Association of America  
Wilczkowski, C. ‘Le témoignage de Tchékhov.”’ Etudes, ccxciv, 263-270. See also 696, 12636. Chernyshevski. 12657. Diiwel, Wolf. “Borkheim und die CernySevskij-Studien von Karl Marx.”  ...  Berdyaev, Nicholas. Dostoevsky. Tr. Donald Attwater. (Living Age Books, LA 15.) N. Y.: Meridian Books. 12661. Bertenson, Sergei. ‘‘The Brothers Karamazov at the Moscow Art Theater.""  ... 

Page 128 of Cremona Vol. 3, Issue 35 [page]

1909 Cremona  
Postacchini £4, Nicholas £6 5s. N. F. Vuillaume £3, Jo. Bapt.  ...  ., labelled Antonius Stradi- varius £23, labelled Guarnerius, with bow in case, £8, Carlo Ferdinandus Landolfi (1770) {12 10s., De Comble £4 15s., Jacintus Santa guiliano (1830) £3, Duke £8, Fendt £4,  ... 

Page 81 of None Vol. 53, Issue 5 [page]

2003 None  
Nicholas F. Landolfi (Protein Design Labs, Fremont, CA). The function-blocking anti-CD62L (anti-L- selectin) MAb LAM1-116 and anti-CD11d (anti-aq) MAb 240I were generously provided by Dr. Thomas F.  ...  Before flow exper- iments, eosinophils (or neutrophils) were allowed to equili- brate at 37°C for 2 min and then were diluted to a cell concentration of 0.5 < 10°/ml in assay buffer at 37°C and perfused  ... 

Page 548 of Journal of Clinical Oncology Vol. 26, Issue SUPPLEMENT [page]

2008 Journal of Clinical Oncology  
3594 8092 5568 Landolfi, Stefania Landreneau, Rodney J.  ...  Lee, Belinda Lee, Bryan C. Lee, Carrie B. Lee, Cathryn C. Lee, Chang Geol Lee, Charles Lee, Chris C. Lee, Christina Ellen Lee, Christopher W. Lee, Dae Ho Lee, Dae Woo Lee, David W.  ... 

Page 22 of Cremona Vol. 3, Issue 26 [page]

1909 Cremona  
Published by C. Woolhouse, 174, Wardour Street, Ww.  ...  Cellos— Kennedy £4, Nicholas Racceris £5 1os., Peter Walmsley £6 ros. Gold-mounted bow by James Tubbs & Sons £5 15s. amongst other things. Ellis, the author of  ... 

AD HOC REVIEWERS

2002 Journal of Immunology  
David Farrar, Michael Farrell, Jay Fathman, C.  ...  Juliana McEver, Rodger McFadden, Grant McGlade, C.  ... 
doi:10.4049/jimmunol.169.12.7137 fatcat:qqmuo7k5ibdwbn6te6gdbp6pm4
« Previous Showing results 1 — 15 out of 75 results